Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 58 recruiting now early-phase tilt #120 of 28,707 conditions

Non-Hodgkin Lymphoma: early-phase trial registry

58 of 107 indexed Non-Hodgkin Lymphoma trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #120 of 28,707 conditions by registered trial count.

107 US clinical trials · 58 currently recruiting · #120 of 28,707 conditions by registered trial count

Non-Hodgkin Lymphoma: 107 US clinical trials tracked, 58 recruiting.

Non-Hodgkin Lymphoma is the subject of 107 registered US clinical trials on ClinicalTrials.gov, 58 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 86 in Phase 1-2 (earlier-stage). The most active sponsor is Baylor College of Medicine, running 7 of these trials.

Enrollment posture brief

Registry condition non-hodgkin-lymphoma

OPEN 58 | RECR 54% | LATE 6 | EARLY 86 | RANK #120 | SPON 7

Nearest open-share peer: Bulimia Nervosa (54% recruiting · 24 trials)

Breast Carcinoma58.9%Non-Hodgkin Lymphoma (this)54%Cognitive Impairment43.4%Crohn's Disease34.9%Hepatitis C12%
Open-enrollment share among volume-matched conditions near Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma lists 58 open slots (54% of 107 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Non-Hodgkin Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Non-Hodgkin Lymphoma is recruiting above its size-band peers.

    58 of 107 indexed trials (54.2%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Non-Hodgkin Lymphoma trials is spread across many organizations.

    Baylor College of Medicine accounts for 7 of 107 trials (6.5%). 77 distinct sponsors appear on at least one study for this condition label.

  3. Most Non-Hodgkin Lymphoma trials plan to enrol fewer than 100 people.

    Median target enrolment is 54 among the 107 trials that report a genuine target (sentinel values excluded). 68 of those (63.6%) plan for fewer than 100 participants.

  4. Non-Hodgkin Lymphoma research is mostly interventional.

    98 interventional and 9 observational studies make up this index (91.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 167Phase 219Phase 34Phase 42

Phase Distribution

PhaseTrial count
Phase 1 67
Phase 2 19
Phase 3 4
Phase 4 2

Named interventions

Most-linked intervention names on Non-Hodgkin Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cyclophosphamide Drug
16 trials
Fludarabine Drug
12 trials
Rituximab Drug
6 trials
Pirtobrutinib Drug
4 trials
Epcoritamab Drug
4 trials
Biospecimen Collection Procedure
4 trials
Venetoclax Drug
4 trials
Tocilizumab Drug
3 trials

US sites by state

Facility locations filed on Non-Hodgkin Lymphoma trials. A trial with sites in several states counts in each.

Texas 33 trials
California 31 trials
New York 30 trials
Ohio 21 trials
Florida 19 trials
Georgia 17 trials
Massachusetts 16 trials
Pennsylvania 15 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Non-Hodgkin Lymphoma page

107 registered trials, 58 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-Hodgkin Lymphoma condition card totals 107 registered trials; most-linked intervention Cyclophosphamide; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.